Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02314923
Recruitment Status : Completed
First Posted : December 11, 2014
Last Update Posted : August 22, 2017
Sponsor:
Collaborators:
BioProtection Systems Corporation
Department of Health and Human Services
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Tracking Information
First Submitted Date  ICMJE December 8, 2014
First Posted Date  ICMJE December 11, 2014
Last Update Posted Date August 22, 2017
Actual Study Start Date  ICMJE December 5, 2014
Actual Primary Completion Date June 23, 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 9, 2016)
  • Percentage of Participants with One or More Solicited Injection-site Adverse Events by Severity [ Time Frame: Up to 14 days postvaccination ]
  • Percentage of Participants with One or More Solicited Systemic Adverse Events by Severity [ Time Frame: Up to 14 days postvaccination ]
  • Percentage of Participants with One or More Adverse Event by Severity [ Time Frame: Up to 56 days postvaccination ]
  • Percentage of Participants with One or More Serious Adverse Event by Severity [ Time Frame: Up to 360 days postvaccination ]
  • Geometric Mean Titers of ZEBOV-specific Immunoglobulin-G (IgG) Antibody [ Time Frame: 28 days postvaccination ]
Original Primary Outcome Measures  ICMJE
 (submitted: December 8, 2014)
  • Frequency, type and severity of adverse events including local injection site and systemic reactogenicity signs and symptoms [ Time Frame: 28 Days ]
  • Evaluation of ZEBOV- specific antibody response by BPSC-1001 [ Time Frame: 28 Days ]
Change History Complete list of historical versions of study NCT02314923 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: February 9, 2016)
  • Optimum dose for general use prophylaxis with BPSC-1001 [ Time Frame: 360 Days ]
  • Mean Copy Number of Vector RNA [ Time Frame: Up to 28 days postvaccination ]
  • Percentage of Participants with Seroconversion for ZEBOV-specific IgG and Neutralizing Antibodies [ Time Frame: Baseline and up to 360 days postvaccination ]
Original Secondary Outcome Measures  ICMJE
 (submitted: December 8, 2014)
  • Define optimum dose for general use prophylaxis with BPSC-1001 [ Time Frame: 360 Days ]
  • Evaluate vaccine viremia after administration of BPSC-1001 [ Time Frame: 28 Days ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)
Official Title  ICMJE A Phase 1 Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Response Study to Evaluate the Safety and Immunogenicity of the BPSC-1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects
Brief Summary Ebola virus has infected and killed people, mostly in Africa. In 2014, the Ebola virus has affected several thousand people. There is no approved effective way to treat or prevent Ebola. Researchers are trying to develop a vaccine for it. This is a study of the anti-Ebola vaccine BPSC-1001 to see if it is safe and to see how it affects people's immune system.
Detailed Description

Between 1994 and the present, there have been many Ebola viruses (EBOV) outbreaks affecting mostly central Africa. However, the 2014 West African outbreak significantly exceeds all previous outbreaks in geographic range, number of individuals affected and in disruption of typical activities of civil society.

This is a Phase 1 safety and tolerability study to evaluate a novel vaccine to Ebola using a live replicating vesicular stomatitis virus (VSV) replacing the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Zaire strain of Ebola (VSVΔG-ZEBOV also known as BPSC-1001).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Ebola Virus
Intervention  ICMJE
  • Biological: BPSC-1001 Vaccine
    Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^3, 3x10^4, 3x10^5, 3x10^6, 9x10^6, 2x10^7, or 1x10^8 pfu.
  • Other: Placebo
    0.9% Saline
Study Arms  ICMJE
  • Experimental: 3x10^3 pfu Vaccine Cohort
    Participants will receive a 1-mL intramuscular injection of BPSC-1001 3x10^3 pfu in the deltoid on Day 0.
    Intervention: Biological: BPSC-1001 Vaccine
  • Experimental: 3x10^4 pfu Vaccine Cohort
    Participants will receive a 1-mL intramuscular injection of BPSC-1001 3x10^4 pfu in the deltoid on Day 0.
    Intervention: Biological: BPSC-1001 Vaccine
  • Experimental: 3x10^5 pfu Vaccine Cohort
    Participants will receive a 1-mL intramuscular injection of BPSC-1001 3x10^5 pfu in the deltoid on Day 0.
    Intervention: Biological: BPSC-1001 Vaccine
  • Experimental: 3x10^6 pfu Vaccine Cohort
    Participants will receive a 1-mL intramuscular injection of BPSC-1001 3x10^6 pfu in the deltoid on Day 0.
    Intervention: Biological: BPSC-1001 Vaccine
  • Experimental: 9x10^6 pfu Vaccine Cohort
    Participants will receive a 1-mL intramuscular injection of BPSC-1001 9x10^6 pfu in the deltoid on Day 0.
    Intervention: Biological: BPSC-1001 Vaccine
  • Experimental: 2x10^7 pfu Vaccine Cohort
    Participants will receive a 1-mL intramuscular injection of BPSC-1001 2x10^7 pfu in the deltoid on Day 0.
    Intervention: Biological: BPSC-1001 Vaccine
  • Experimental: 1x10^8 pfu Vaccine Cohort
    Participants will receive a 1-mL intramuscular injection of BPSC-1001 1x10^8 pfu in the deltoid on Day 0.
    Intervention: Biological: BPSC-1001 Vaccine
  • Placebo Comparator: Placebo Cohort
    Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0.
    Intervention: Other: Placebo
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 9, 2016)
512
Original Estimated Enrollment  ICMJE
 (submitted: December 8, 2014)
320
Actual Study Completion Date  ICMJE June 23, 2016
Actual Primary Completion Date June 23, 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Subject Inclusion Criteria:

  1. Healthy adult male or non-pregnant, non-lactating adult female, ages 18 to 60 (inclusive) at the time of screening
  2. Have provided written informed consent prior to screening procedures
  3. Free of clinically significant health problems, as determined by pertinent medical history, physical examination and clinical judgment of the investigator.
  4. Available, able, and willing to participate for all study visits and procedures.
  5. Males and females who are willing to practice abstinence from sexual intercourse with the opposite sex, or willing to use effective methods of contraception, from at least 30 days prior to vaccination until study end.
  6. Be willing to minimize blood and body fluid exposure of others for 7 days after vaccination by:

    1. Using effective barrier prophylaxis, such as latex condoms, during penetrative sexual intercourse
    2. Avoiding the sharing of needles, razors, or toothbrushes
    3. Avoiding open-mouth kissing
  7. Resides in the geographic area of a clinical study site for 1 year after vaccination without risk of deployment outside the U.S.

Subject Exclusion Criteria:

Subjects meeting any of the following criteria will be excluded from the study:

  1. History of prior infection with a filovirus or prior participation in a filovirus vaccine trial
  2. History of prior infection with VSV or receipt of a VSV vectored vaccine
  3. Has been involved in the care in any capacity of a patient with Ebola virus infection within the previous 21 days
  4. Is a healthcare worker who has direct contact with patients (nurse, physician, dentist, emergency medical technician, dental hygienist)
  5. Has a house-hold contact (HHC) who is immunodeficient, on immunosuppressive medications, human immunodeficiency virus (HIV)-positive, pregnant, has an unstable medical condition
  6. Has an HHC, or is a childcare worker who has direct contact with children, 5 years of age or younger
  7. Direct hands-on job preparing food in the food industry
  8. History of employment in an industry involved in contact with ruminant animals, veterinary sciences, or other potential exposure to VSV
  9. History of employment or activity which involves potential contact with filoviruses
  10. History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions
  11. Known allergy to the components of the BPSC1001 vaccine product
  12. Receipt of investigational product up to 30 days prior to randomization or ongoing participation in another clinical trial
  13. Receipt of licensed non-live vaccines within 14 days of planned study immunization (30 days for live vaccines)
  14. Ability to observe possible local reactions at the eligible injections sites (deltoid region) is, in the opinion of the investigator, unacceptably obscured due to a physical condition or permanent body art
  15. Acute or chronic, clinically significant psychiatric, hematologic, pulmonary, cardiovascular, or hepatic or renal functional abnormality as determined by the investigator based on medical history, physical examination, and/or laboratory screening test. This would include a known hemoglobinopathy or coagulation abnormality.
  16. Any baseline laboratory screening test which in the opinion of the investigator, is considered clinically significant
  17. Any serologic evidence of hepatitis B or C infection
  18. Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV-1, HIV-2 infection, cytotoxic therapy in the previous 5 years, and/or diabetes
  19. Any chronic or active neurologic disorder, including migraines, seizures, and epilepsy, excluding a single febrile seizure as a child
  20. Have a known history of Guillain-Barré Syndrome
  21. Have an active malignancy or history of metastatic or hematologic malignancy
  22. Suspected or known alcohol and/or illicit drug abuse within the past 5 years
  23. Moderate or severe illness and/or fever >100.4°F within 1 week prior to vaccination (subjects can be rescheduled)
  24. Pregnant or lactating female, or female who intends to become pregnant during the study period
  25. Administration of IgGs and/or any blood products within the 120 days preceding study entry or planned administration during the study period
  26. History of blood donation within 60 days of enrollment or plans to donate within the study period
  27. Administration of chronic (defined as more than 14 days) immunosuppressants or other immune modifying drugs within 6 months of study entry

    1. For corticosteroids, this includes prednisone, or equivalent, greater than or equal to 0.5 mg/kg/day
    2. Intranasal, topical, and intra-articular steroids are allowed
  28. Unwilling to allow storage and use of blood for future vaccine research

28. Research staff or the immediate family of research staff directly involved with the clinical study.

29. Unwilling to undergo diagnostic evaluation of joint signs and symptoms, which may include arthrocentesis if clinically indicated based on presence of effusion and if the procedure is acceptable to the subject at the time (Cohort 2 only) 30. Unwilling to undergo diagnostic evaluation of skin rash, to include punch biopsy if clinically indicated and if the procedure is acceptable to the subject at the time (Cohort 2 only) 31. Research staff or the immediate family of research staff directly involved in the clinical study 32. Any other significant finding that in the opinion of the investigator would increase the risk of the individual having an adverse outcome from participating in this study 33. Elective surgery or hospitalization planned during the period of study participation 34. Subject has traveled to an area where the World Health Organization has declared as an Ebola outbreak zone 35. History of chronic inflammatory disease (e.g., rheumatoid arthritis, psoriatic arthritis, reactive arthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, Crohn's disease, ulcerative colitis, and gout), symptomatic osteoarthritis, or any other autoimmune or autoinflammatory disorder

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 60 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries United States
 
Administrative Information
NCT Number  ICMJE NCT02314923
Other Study ID Numbers  ICMJE V920-004
NLG0507 ( Other Identifier: NewLink Genetics Corp. )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Merck Sharp & Dohme Corp.
Study Sponsor  ICMJE Merck Sharp & Dohme Corp.
Collaborators  ICMJE
  • BioProtection Systems Corporation
  • Department of Health and Human Services
Investigators  ICMJE
Study Director: Medical Director Merck Sharp & Dohme Corp.
PRS Account Merck Sharp & Dohme Corp.
Verification Date August 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP